Abstract
To assess the success of a human papillomavirus (HPV) vaccination program among adolescent girls aged 9-14 years in Haiti and to understand predictors of completion of a two-dose HPV vaccination series. Data collection was conducted during HPV vaccination campaigns in Port-au-Prince between August 2016 and April 2017. Descriptive statistics and logistic regression models were used to examine characteristics associated with vaccination series completion of school based and non-school based vaccination delivery modalities. Of the 2,445 adolescent girls who participated in the awareness program, 1,994 participants (1,307 in non-school program, 687 in school program) received the first dose of the vaccine; 1,199 (92%) in the non-school program and 673 (98%) in the school program also received the second dose. Menarche (OR: 1.87; 95% CI, 1.11-3.14), if the participant was a prior patient at the GHESKIO clinics (OR: 2.17; 95% CI, 1.32-3.58), and participating in the school-based program (OR: 4.17; 95% CI, 2.14-8.12) were significantly associated with vaccination completion. Vaccination in school- and non-school-based settings was successful, suggesting that a nationwide HPV vaccination campaign using either approach would be successful using either approach.
Highlights
Cervical cancer is the fourth most prevalent cancer in women and the fourth most frequent cause of cancer-related deaths among women worldwide [1]
Menarche (OR: 1.87; 95% confidence interval (CI), 1.11–3.14), if the participant was a prior patient at the GHESKIO clinics (OR: 2.17; 95% CI, 1.32–3.58), and participating in the school-based program (OR: 4.17; 95% CI, 2.14–8.12) were significantly associated with vaccination completion
A total of 2,445 adolescent girls participated in the awareness campaigns. 1,698 girls participated in the non-school cohort and 747 in the school cohort
Summary
Cervical cancer is the fourth most prevalent cancer in women and the fourth most frequent cause of cancer-related deaths among women worldwide [1]. Most cases of cervical cancer are caused by infection with a high-risk strain of human papillomavirus (HPV) [4,5,6]. In the Caribbean region, the prevalence of the high-risk strains HPV 16/18 in women with normal cervical cytology is estimated to be 15.8% [7]. The World Health Organization (WHO) recommends vaccination against HPV in girls aged 9 to 14, targeting primarily those who are not yet sexually active [13]. For girls aged 9 to 14, a two-dose schedule is recommended for cost effectiveness and to facilitate higher coverage in adolescents
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
